Pamela Sklar, MD, PhD, Elected to the Institute of Medicine
Pamela Sklar, MD, PhD, Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences, at the Icahn School of Medicine at Mount Sinai, has been elected to the Institute of Medicine (IOM) of the National Academy of Sciences. Membership is one of the highest honors in the field of medicine.
Each year, the IOM elects members who have demonstrated excellence in advancing our nation’s health. Members volunteer their service on IOM committees, boards, and other activities. As the Founding Chief of Mount Sinai’s new Division of Psychiatric Genomics, Dr. Sklar is building a world-class psychiatric genomics unit that will be a leader in understanding the genetic causes of psychiatric disorders such as schizophrenia and bipolar disorder. Her team, which includes leaders in statistical genetics, stem cell biology, neurocognition, and imaging, will pioneer ways to translate these genetic insights into the clinical practice of psychiatry.
“This election is truly one of the greatest honors of my career,” said Dr. Sklar. “I hope to contribute to the IOM on issues regarding the role of genetics in personalized medicine, ethical questions surrounding genetic testing for psychiatric diseases, and translating research findings into the clinical setting. By understanding genetic risk factors, physicians can target psychiatric diseases at their roots, and intervene earlier with treatment.”
Dr. Sklar has a long track record of leadership in collaborative research settings, including the Psychiatric Genomics Consortium. Her research focuses on rare and common DNA and RNA variations and utilizes the newest high-throughput genomic technology in mental illness. In addition, Dr. Sklar has made integral contributions to the understanding of gene and structural variants that increase the risk of bipolar disorder and schizophrenia.
"I also congratulate Dr. Sklar for this outstanding honor from the IOM," said Dr. Charney. "Her research has greatly enhanced our understanding of the role of genetic variants in mental illness, and supports Mount Sinai’s commitment to precision medicine, by developing therapies tailored to individual patient needs through the application of genomic information.”